17 results about "Aspartylglutamate" patented technology

The invention discloses a gelator and a preparation method and application thereof, the structural formula of the gelator is # imgabs0 #, R1 is a side chain group connected to an amino acid central carbon atom except an amino group, a carboxyl group and a hydrogen atom; the amino acid is selected from one of glycine, alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine, selenocysteine and pyrrole lysine; the amino acid is selected from one of glycine, alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine, selenocysteine and pyrrole lysine; r2 is alkyl with the carbon atom number of 16 to 19; and R3 is 9-fluorenyl methoxy carbonyl group or t-butyloxycarbonyl group. The gelator has a hydrophobic long alkyl tail chain, can spontaneously gather and assemble into a three-dimensional network structure through hydrogen bonds, pi-pi interaction and hydrophobic force, and fixes an oil phase in an oil solvent or an oil-water mixture in an effective manner to form high-strength gel.

The invention discloses a cod bone-derived high-activity calcium chelating peptide and a preparation method thereof, and belongs to the technical field of functional biological product preparation. The calcium chelating peptide provided by the invention is derived from a cod bone collagen enzymatic hydrolysate and is obtained through affinity chromatography separation of hydroxyapatite, the calcium chelating activity is 4.9-5.2 mu g / mg, and the calcium chelating peptide contains aspartic acid and glutamic acid enriched peptide fragments, through deep processing of cod bones, high-valued utilization of cod bone resources is realized, the high-activity calcium chelating peptide is prepared, and the calcium chelating peptide has a wide application prospect. And a high-quality raw material is provided for the development of a novel calcium supplement.

The invention relates to the technical field of collagen, and provides cross-linked collagen and a preparation method and application thereof in the field of medical cosmetology, the preparation method of the cross-linked collagen comprises the following steps: collagen and an oxazoline compound are subjected to a cross-linking reaction under the condition that the pH value is 5-8, glycine is added to terminate the reaction after the reaction is finished, and the cross-linked collagen is obtained. And then cleaning, centrifuging and drying to obtain the cross-linked collagen. The oxazoline compound is subjected to ring-opening reaction with carboxyl (such as aspartic acid and glutamic acid) and amino (such as lysine and arginine) on a side chain of collagen to form a stable amido bond or similar covalent bond structure, so that efficient crosslinking is realized; and the oxazoline compounds do not contain free aldehyde groups, so that toxic by-products are not generated in the reaction process, and the unification of'high efficiency 'and'safety' is realized.

The invention relates to an isolated peptide having an amino acid sequence selected from the group consisting of: Pro-Val-Leu-Lys (SEQ ID NO: 1); Pro-Leu-Pro-Arg (SEQ ID NO: 2); Glu-Ala-Glu-Phe-Asp (SEQ ID NO: 3); Pro-Glu-Arg-Asn-Glu (SEQ ID NO: 4); Pro-Gln-Pro-Glu-Arg (SEQ ID NO: 5); Glu-Phe-Asp-Glu-Lys-Pro-Ala-Asp (SEQ ID NO: 6); Glu-Asp-Ala-Pro-Val-Leu-His (SEQ ID NO: 7); Glu-Phe-Asp-Ala-Arg-Pro-Thr (SEQ ID NO: 8); Glu-Glu-Thr-Pro-Ser-His-Asp (SEQ ID NO: 9); Glu-Glu-Val-Glu-Glu-Glu-Glu-Val-Glu (SEQ ID NO: 10); Glu-Phe-Asp-Glu-Lys-Ala-Pro-Asp (SEQ ID NO: 11); Glu-Asn-Ala-Pro-Asp-Gln-Lys (SEQ ID NO: 12); Glu-Asp-Met-Ala-Pro (SEQ ID NO: 13); Pro-Ile-Asn-Asp-Asn (SEQ ID NO: 14); Pro-Thr-Asp-Leu (SEQ ID NO: 15); Pro-Val-Ala-Glu (SEQ ID NO: 16); Arg-Asn-Gly-Pro-Arg (SEQ ID NO: 17); Arg-Ala-Glu-Asp-Thr-Ala-Thr-Tyr-Tyr (SEQ ID NO: 18); Glu-Gly-Asp-Ser-Ala-Ala-Ile (SEQ ID NO: 19); Glu-Pro-Glu-Gly-Asp-Val-His-Gln (SEQ ID NO: 20); and Glu-Asp-Glu-Val-Leu-Ala-Thr-Pro (SEQ ID NO: 21), a protein hydrolysate comprising the isolated peptides, and use thereof as a taste-modulating agent in food and pharmaceutical preparations.

A hydrogelling peptide having the sequence X1-WTW–Link–WTW-X2 (eg. SWTW–Link– WTWK.) X1 and X2 are independently selected from any amino acid, for example Leucine (L), Isoleucine (I), Valine (V), Alanine (A), Methionine (M), Phenylalanine (F), Tryptophan (W), Proline (P), Glycine (G), Serine (S), Asparagine (N), Glutamine (Q), Threonine (T), Cysteine (C), Tyrosine (Y), Aspartic acid (D), Glutamic acid (E), Lysine (K), Arginine (R) or Histidine (H), where Link is a peptide motif selected to provide the hydrogelling peptide with hydrogelling properties. Link can be any number (e.g. 4-8) amino acid residues, for example, Link is a four amino acid residue of the following formula -aa1-GN-aa2- where aa1 and aa2 are independently selected from E, K, V or Q, (e.g. X1-WTWQGNVWTW-X2). Also the resultant hydrogels and methods of controlling mechanical properties (for example stiffness) of hydrogels and controlling basal-out: apical-out generation of organoids.

The present application belongs to the technical field of organic waste resource utilization, and particularly relates to a composite nutrient agent for regulating and controlling product spectrum of organic waste anaerobic fermentation, a method and application, the composite nutrient agent comprising energy substrate, organic nitrogen source, B group vitamins and mineral buffer elements, wherein: the energy substrate comprises lactic acid, acetic acid, glucose, xylose and arabinose; the organic nitrogen source comprises crude protein containing full-spectrum amino acids, the full-spectrum amino acids comprising aspartic acid, glutamic acid, alanine and leucine; the B group vitamins comprising vitamin B1, vitamin B2 and vitamin B6; and the mineral buffer elements comprising potassium, calcium and magnesium elements. The present application introduces the composite nutrient agent into a chain extension system with organic waste as a substrate, and provides a new regulation strategy and special additive for high-value utilization of organic waste.

The present invention provides an alkyne amide compound having a structure represented by formula (I), or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and uses thereof. Specifically provided is the use of the alkyne amide compound, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, in the selective modification of protein amino acid residues, preferably, the amino acid is aspartic acid, glutamic acid, and / or cysteine. Also provided is the use of the alkyne amide compound, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, in the preparation of a kinase inhibitor, wherein the kinase is EGFR, ALDH1, GAPDH, MEK2, ECH1, GAPDH, and / or ALDH1. Also provided is the use of the alkyne amide compound, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, in the preparation of a drug for preventing and / or treating tumors.

The present invention provides a tobacco filler that allows flexibility in the ratio of saccharides to amino acids in tobacco sheet form. The tobacco filler comprises a first tobacco sheet, a second tobacco sheet, or a combination thereof. Each of the first and second tobacco sheets contains three saccharides selected from glucose, fructose, sucrose, and mixtures thereof, and three amino acids selected from aspartic acid, glutamic acid, asparagine, and mixtures thereof. The first tobacco sheet has a saccharide-to-amino acid mass ratio of 50 or more, while the second tobacco sheet has a saccharide-to-amino acid mass ratio of 20 or less.

An extracellular vesicle separation method, a colloidal particle, and a preparation method thereof are provided. The colloidal particle is used for extracellular vesicle separation, and includes 2 wt % to 6 wt % of agarose. The colloidal particle has a particle size of 25 μm to 500 μm, and is surface-modified with biocompatible molecules. The biocompatible molecules include sodium carboxymethyl cellulose (CMC), methyl cellulose (MC), glycine, aspartic acid, glutamic acid, bovine serum albumin (BSA), fetal bovine serum (FBS), or a combination thereof.

The embodiment of the invention relates to the technical field of targeted imaging molecules, and discloses a linker, a targeted ligand, a radiopharmaceutical and a preparation method and application thereof. Wherein the linker is composed of 2-3 amino acids, the amino acids at least comprise acidic amino acids, the acidic amino acids are selected from one or more of aspartic acid, glutamic acid and 3-sulfoalanine, and the linker is used for coupling a targeted pharmacophore and a radionuclide binding group to prepare a targeted ligand and a targeted radiopharmaceutical. The connexon has the characteristics of high hydrophilicity and high binding force with plasma protein by limiting the number of amino acids and selecting acidic amino acids, so that the tumor uptake and residence time are prolonged, and the imaging contrast ratio is further improved.

A mutant E1A antagonizing ubiquitination-mediated degradation and its use in the preparation of potentiated oncolytic adenoviruses and immune potentiators are provided. The mutant E1A is obtained by mutating lysine residues at positions 253 and 285 of a wild-type E1A to any one of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, aspartic acid, glutamic acid, arginine, or histidine. The mutation is capable of reducing the degradation of a key adenoviral replication protein E1A and maintaining its high level expression, thereby promoting replication of oncolytic adenovirus, improving tumor killing effect, and holding broad clinical application prospects.

The application discloses a gel factor and a preparation method and application thereof. A structural formula of the gel factor is shown in the following formula: wherein R1 is a side chain group except for an amino group, a carboxyl group and one hydrogen atom connected to a central carbon atom of an amino acid, and the amino acid is selected from one of glycine, alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine and selenocysteine; R2 is an alkyl group with 16-19 carbon atoms; and R3 is a 9-fluorenylmethyloxy carbonyl group or a tert-butyloxy carbonyl group. The gel factor has a hydrophobic long alkyl tail chain, can spontaneously aggregate and assemble into a three-dimensional network structure through hydrogen bonds, pi-pi interaction and hydrophobic force, and can effectively fix oil solvents or oil phases in oil-water mixtures to form a high-strength gel.

The present application relates to a kind of lithium adsorbent and its preparation method and application, the method includes the following steps: providing first mixture, the first mixture includes water-soluble lithium salt, water-soluble aluminum salt and silane amino acid;The first mixture is coprecipitation with alkaline solution, and second mixture is obtained;And the second mixture is aged;Wherein, by water-soluble amino acid and isocyanate silane are prepared the silane amino acid;The water-soluble amino acid includes aspartic acid, glutamic acid, histidine, lysine, arginine, serine, threonine, cysteine, asparagine, glutamine one or more thereof.The preparation method of an embodiment of the present application is prepared lithium adsorbent, with high cyclic adsorption capacity, stable performance, long service life characteristics.

The present invention relates to compositions comprising sHDL nanoparticles. In particular, the present invention relates to sHDL nanoparticles comprising a phospholipid; an apoplipoprotein mimetic; a thiol-reactive lipid; and a peptide comprising a linker moiety connected with a payload moiety, wherein the linker comprises cysteine (C) and one to five amino acids independently selected from aspartic acid (D), glutamic acid (E), and serine (S), the payload comprises a polypeptide that is 5 to 35 amino acids in length and has a net positive charge at a pH of 7 to 12, and the peptide comprises a net negative charge at a pH of 7 and an isoelectric point of 0.4 to 12; and wherein the peptide is covalently attached to the thiol-reactive lipid by way of the cysteine (C).

The invention provides a solid electrolyte coating, a composite diaphragm and application, the solid electrolyte coating comprises a solid electrolyte, a binder and a wetting agent, and also comprises acidic amino acid as a binder reinforcing agent; the acidic amino acid comprises one or more of aspartic acid, glutamic acid and near-end cysteine; the mass of the acidic amino acid is 0.4-0.6% of the mass of the solid electrolyte; the binder has a fluorine-containing substituent group and / or an oxygen-containing substituent group. The amino acid is used for enhancing the bonding capacity of the adhesive and enhancing the peel strength of the coated diaphragm, so that the consumption of auxiliaries such as the adhesive is reduced, and diaphragm holes are prevented from being blocked by excessive auxiliaries. Lewis alkaline sites exist on the surface of the adopted lithium and sodium solid electrolyte, amino acid molecules are combined with the Lewis alkaline sites through carboxyl, solid electrolyte particles are coated, and the coating can reduce the surface energy of the lithium and sodium solid electrolyte particles and enhance the wettability.

The present invention relates to a composition comprising sHDL nanoparticles. In particular, the present invention relates to sHDL nanoparticles comprising a phospholipid; an apolipoprotein mimetic; a thiol reactive lipid; and a peptide comprising a linker moiety linked to a payload moiety wherein the linker comprises cysteine (C) and one to five amino acids independently selected from aspartic acid (D), glutamic acid (E) and serine (S), the payload comprising a polypeptide having a length of 5 to 35 amino acids and having a net positive charge at pH 7 to 12, and the peptide comprises a net negative charge at pH 7 and an isoelectric point from 0.4 to 12; and wherein the peptide is covalently linked to the thiol-reactive lipid via the cysteine (C).

This invention belongs to the field of preparation and stabilization technology of functional inorganic nanocomposites, specifically disclosing an ACC nanoparticle stabilizer and its application. This invention uses a single amino acid such as aspartic acid, glutamic acid, and lysine, or a mixture of multiple amino acids, as the amino acid source, and phosphoric acid solution as the phosphorus source. By controlling the reaction temperature at 130-220℃ and the reaction time at 1-5 hours, hydrothermal polymerization is achieved to prepare ACC nanoparticle stabilizers. The hydrothermal method does not require complex catalysts, has mild reaction conditions, and is suitable for acidic, alkaline, and mixed amino acid systems, exhibiting strong versatility. The hydrothermal product can be directly concentrated and used without separation and purification, which not only reduces preparation costs but also helps improve the stability of ACC nanoparticles, solving the problem of insufficient long-term stability and easy crystallization of ACC nanoparticles. It has the advantages of being green and efficient, highly controllable, and biosafe.